ArticleThe Journal of infection2020
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
Open access · bronzeAbstract readLetterComment
In one paragraph
Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 8 pooled it
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 8 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis.Respiratory medicine · 2022Pooled it
- JAK inhibitors and COVID-19.Journal for immunotherapy of cancer · 2022Pooled it
- Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.Expert review of anti-infective therapy · 2022Pooled it
- Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.Frontiers in medicine · 2022Pooled it
- Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Pooled it
- JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Pooled it
- Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.EBioMedicine · 2025Trial
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2022Trial
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.The Lancet. Respiratory medicine · 2021Trial
- Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.Clinical and translational science · 2021Trial
- Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Annals of the rheumatic diseases · 2024Review
- COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.Genes & diseases · 2023Review
- Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats.Annals of surgery · 2023Article
- Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.Signal transduction and targeted therapy · 2023Review
- Review
- Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review.Biology · 2023Review
- Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.Frontiers in immunology · 2023Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
17 authors at 6 institutions in 1 country.
Fabrizio CantiniRheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: fbrzcantini@gmail.com.
Laura NiccoliRheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.
Carlotta NanniniRheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.
Daniela MatarreseSanitary Direction, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.
Massimo Edoardo Di NataleII Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: massimoedoardo.dinatale@uslcentro.toscana.it.
Pamela LottiII Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: pamela.lotti@uslcentro.toscana.it.
Donatella AquiliniDivision of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: donatella.aquilini@uslcentro.toscana.it.
Giancarlo LandiniDepartment of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: giancarlo.landini@uslcentro.toscana.it.
Barbara CimolatoDepartment of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: barbara.cimolato@uslcentro.toscana.it.
Massimo Antonio Di PietroDivision of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: massimoantonio.dipietro@uslcentro.toscana.it.
Michele TrezziDivision of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: michele.trezzi@uslcentro.toscana.it.
Paolo StobbioneRheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.
Gabriele FrausiniDivision of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano-Pesaro, Italy. Electronic address: gabriele.frausini@ospedalimarchenord.it.
Assunta NavarraClinical epidemiology Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy. Electronic address: assunta.navarra@inmi.it.
Emanuele NicastriClinical Division of Infectious Diseases, National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy. Electronic address: emanuele.nicastri@inmi.it.
Giovanni SotgiuClinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. Electronic address: gsotgiu@uniss.it.
Delia GolettiTranslational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.
Azienda Usl Toscana Centro · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITHospital of Prato · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITOspedali Riuniti Marche Nord · ITUniversity of Sassari · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Coronavirus InfectionsPandemicsPneumonia, ViralAzetidinesBetacoronavirusCOVID-19HumansPilot ProjectsPurinesPyrazolesSARS-CoV-2SulfonamidesAzetidinesbaricitinibPurinesPyrazolesSulfonamidesBaricitinibCOVID-19JAK1/2PneumoniaRetrospective studySARS-Co-V2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.